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Abstract
The extracellular matrix (ECM) forms a mesh surrounding tissue, made up of 
fibrous and non-fibrous proteins that contribute to the cellular function, mechan-
ical properties of the tissue and physiological function of the organ. The cardiac 
ECM remodels in response to mechanical alterations (e.g., pressure overload, vol-
ume overload) or injuries (e.g., myocardial infarction, bacterial infection), which 
further leads to mechanical and functional changes of the heart. Collagen, the 
most prevalent ECM protein in the body, contributes significantly to the mechani-
cal behavior of myocardium during disease progression. Alterations in collagen 
fiber morphology and alignment, isoform, and cross-linking occur during the 
progression of various cardiac diseases. Acute or compensatory remodeling of 
cardiac ECM maintains normal cardiac function. However, chronic or decompen-
satory remodeling eventually results in heart failure, and the exact mechanism of 
transition into maladaptation remains unclear. This review aims to summarize the 
primary role of collagen accumulation (fibrosis) in heart failure progression, with 
a focus on its effects on myocardial tissue mechanical properties and cellular and 
organ functions.
Keywords: collagen deposition, fibrosis, myocardial stiffening, left and right 
ventricle, mechanobiology
1. Introduction
The extracellular matrix (ECM) is a network of proteins, fibrous and non-
fibrous, which form a supporting architecture for the cells in cardiac tissues. 
Cardiomyocytes, fibroblasts, vascular cells, and inflammatory cells that are 
responsible for the synthesis and degradation of ECM proteins exist in and around 
the cardiac ECM. A unique hallmark of the cardiovascular (CV) system is that the 
tissue is subject to dynamic mechanical load from the pulsatile blood pressure and 
flow. A perturbation of the mechanical load will be transduced to and sensed by 
the cells via the ECM to trigger acute or chronic remodeling of the tissue, resulting 
in structural and mechanical changes in the ECM. The altered ECM biomechanical 
properties further change the behavior of the cells within the tissue. These aspects 
are known as mechanobiology. This chapter will focus primarily on the changes of 
the ECM in various cardiac diseases, the alterations in the mechanical properties 
of the myocardium as a result of the ECM remodeling, and the impact of these 
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biomechanical factors on cellular and organ function in the progression of heart 
failure (Figure 1). Moreover, because collagen accumulation (fibrosis) is mostly 
investigated and contributes significantly to myocardial mechanical properties, 
we will limit our discussion on cardiac fibrosis as the main ECM remodeling event. 
Readers are referred to other extensive reviews that have summarized a broad 
category of ECM proteins during myocardial remodeling in different types of heart 
diseases [1, 2].
2. Extracellular matrix proteins in cardiac tissues
2.1 Overview of extracellular matrix proteins in biological tissues
Extracellular matrix (ECM) proteins found in biological tissue can serve struc-
tural or non-structural roles, depending on the location and composition of the 
protein. Glycoproteins primarily consist of structural ECM proteins, which include 
fibrillar collagen, elastin, fibronectin, and laminin [1]. These are often the main 
determinants of tissue’s passive mechanical properties. The non-structural ECM 
proteins are primarily categorized as proteoglycans, which are further distinguished 
as four subgroups—hyalectans, cell surface proteoglycans, basement membrane 
proteoglycans, and small leucine-rich proteoglycans (SLRP’s) [2]. These proteins 
play a key role in cell–cell or Cell—matrix interactions, interaction with growth 
factors, as well as binding to cell receptors to regulate cellular function [2].
Among the structural ECM proteins, collagen and elastin are mostly investigated 
in cardiovascular tissues. Collagen is the most abundant protein in the body and 
formed from the basic unit of tropocollagen [3]. Tropocollagens, made up of poly-
peptide chains, spontaneously twist together to form a triple helix structure, which 
form a newly synthesized procollagen fibril. Mature collagen fibers can then form 
via cross-linking of procollagen fibrils into bundles or sheets, conferring versatile 
mechanical properties in various tissues [3]. There are over 25 collagen types to date 
[2], each with different physical and mechanical properties [4]. For instance, type 
I collagen is a subtype that exhibits stiffer mechanical property and higher tensile 
strength compared to type III collagen. Collagen metabolism is maintained by the 
synthesis and degradation balance, and different tissues have different turnover 
rates [4, 5]. Higher turnover of collagen types I and III is observed in diseased 
Figure 1. 
A schematic plot showing the relations between cardiac ECM remodeling (fibrosis), tissue mechanics and 
ventricular function.
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tissues, and is also linked to the pathological state of the tissue such as inflamma-
tion and aging [4, 5]. Overall, fibrillar collagen contributes to CV tissue’s nonlinear 
elastic behavior at high strains due to the increased recruitment of fibers.
Elastin is another primary structural protein, contributing to the mechanical 
property of the CV tissue at low strains [6]. It is formed as sheets comprised of the 
base unit tropoelastin, which has the ability to stretch and recoil [6]. Compared 
to collagen fibers which have an average Young’s Modulus of 250–400 MPa [7], 
elastin fibers are more compliant with an average Young’s Modulus of 1 MPa [8]. 
Elastin is a highly stable protein that has very low turnover rate – once formed, it 
lasts almost for the entire lifespan [9]. Increased elastin degradation or damage is a 
sign of pathological remodeling of the tissue and is associated with aging and CV 
diseases [9].
2.2 Primary ECM proteins in the heart
In the myocardial tissue, the main ECM protein is collagen. Collagen is diffu-
sively spread over in the myocardium—interstitial and perivascular collagen fibers 
have been revealed by histology. Collagen types I and III are the most prominent 
collagen types in the myocardium [10], making up 85% and 6–11% of the total col-
lagen, respectively [11]. Other isoforms of collagen are also reported. Bashey et al. 
examined murine, canine, and nonhuman primate healthy hearts and found that 
type V collagen comprises 2 ~ 3% and type VI collagen comprises ~5% of the total 
collagen in the myocardium [11]. While the fractional content of type IV collagen 
was not evident, it appeared most prominent in the basement membrane and in the 
media [11]. A detailed summary of all fibrillar and non-fibrillar collagen and their 
roles in cardiac diseases can be found in a recent review [12].
Elastin content in the ventricle is not detailed in the same manner as collagen. 
The distribution of elastin is mainly limited to the epicardium, the outer layer of the 
ventricular wall [13, 14]. Biochemical measurements showed that elastin content 
is about one tenth of the collagen content in healthy heart. Furthermore, the left 
ventricle (LV) tended to have more elastin and collagen content (in μg/mg) than the 
right ventricle (RV) [15].
In heart valves, elastin is more abundant than in the myocardium. It is located 
primarily in the inflow layer and sparsely distributed in the outflow and central lay-
ers, comprising approximately 10% of total proteins in the tissue [16, 17]. Collagen 
type I is found primarily in the valve leaflets and the valve outflow layer, whereas 
collagen type III is distributed throughout the entire valve structure [16]. Collagen 
comprises approximately 60% of ECM proteins in human heart valves [17].
2.3 Cells and molecules responsible for ECM synthesis and degradation
The cellular components responsible for the cardiac collagen synthesis include 
interstitial fibroblasts (in healthy hearts), transdifferentiated myofibroblasts and 
inflammatory cells (in diseased hearts), cardiomyocytes, and adventitial fibroblasts 
and smooth muscle cells (SMCs) in the blood vessels [18–20]. Several biological 
mediators such as pro-inflammatory cytokines, growth factors and hormones are 
also identified to participate in collagen synthesis, which are reviewed previously 
[4, 21, 22]. Among them, fibroblasts and transforming growth factor beta (TGF-β) 
are two main contributing factors. In cardiac remodeling, fibroblasts migrate to the 
injured region or to the area where ECM proteins are over-degraded and secrete 
new ECM proteins—primarily collagen types I and III [18]. Moreover, a “new” 
phenotype of cells myofibroblasts, emerge in injured myocardium, which is a key 
step to strengthen cardiac fibrosis in both infarcted and hypertensive myocardium. 
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TGF-β is involved in signaling pathways of various cells (fibroblasts, cardiomyo-
cytes, immune and vascular cells) to initiate fibrogenic action [19]. For a thorough 
review of current understanding of cardiac fibrosis in ischemic and non-ischemic 
heart diseases, the reader is referred to these references [12, 21].
Degradation of the ECM proteins is necessary for the turnover as well as normal 
protein function. Matrix metalloproteinases (MMPs) are the most significant 
molecules that contribute to this degradation and these enzymes are key in the CV 
tissue remodeling [10]. MMPs in the heart are primarily expressed by the fibroblasts 
and cardiomyocytes [20, 23]. Table 1 details various types of MMPs and the ECM 
proteins that they target. Insoluble fibrillar collagen such as collagen type I and III 
or more cross-linked collagen is difficult to be enzymatically degraded [11]. To pre-
vent excessive degradation of ECM, tissue inhibitors of metalloproteinases (TIMPs) 
are secreted to bind to MMPs and limit the role of activated MMPs. Therefore, 
the overall balance between the activated MMPs and TIMPs determines the ECM 
remodeling and turnover rate.
3. Measurement of ECM proteins
There is increasing agreement that the ECM is not a passive biological compo-
nent but actively interferes with cellular and organ function in the dynamic remod-
eling process. Thus, the measurement of ECM proteins is critical to study their roles 
in tissue biomechanics and remodeling in various diseases. The existing measure-
ment methods can be classified into these categories: medical imaging techniques, 
optical imaging techniques, biochemical and biological methods.
3.1 Medical imaging techniques
Medical imaging techniques are generally noninvasive because they can be 
performed on a live subject with negligible risks; they are sometimes referred to as 
organ-scale imaging [25]. Primary medical imaging techniques include Magnetic 
Resonance Imaging (MRI), ultrasound and nuclear imaging. These techniques 
could measure bulk quantities of the materials—concentration, volume fraction 
and distribution of proteins.
MRI is the most common imaging method for collagen detection because of its 
higher sensitivity to specific molecular probes to target specific ECM proteins [26]. 
MMPs Substrate
MMP-1 Collagens I, II, III, VII, X
MMP-8 Collagens I, II, III, V, VII, X
MMP-13 Collagens I, II, III, IV, fibronectin, laminin
MMP-2 Collagens, I, IV, V, VII, X, XI, fibronectin, laminin elastin
MMP-9 Collagens III, IV, V, VII, X, elastin
MMP-3 Collagens III, IV, V, IX, X, fibronectin, laminin
MMP-10 Collagens III, IV, V, IX, laminin, fibronectin
MMP-11 Collagen IV, fibronectin, laminin
MMP-14 Collagens I, II, III, fibronectin, laminin
Table 1. 
Matrix Metalloproteinases (MMPs) and their substrates (adapted from [24]).
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For example, the feasibility of detection of collagen (predominantly collagen type I) 
using a gadolinium-containing molecular contrast agent (delayed or late gadolinium 
enhancement) has been demonstrated in preclinical animal studies [27, 28]. The 
technique is valuable in the detection of fibrosis in ventricles [29, 30]. Recently, T1 
mapping technique has emerged as a more useful technique for diffuse interstitial 
fibrosis measurement [31, 32]. In addition, a particular mode of MRI, tagging and 
feature tracking, enables clinicians to measure tissue strain from which collagen 
measurements can be indirectly deduced [33]. Elastin content can be quantified 
directly by molecular MRI as well [34].
Ultrasound technique is another imaging method to quantify collagen or elastin. 
Strain elastography measures elasticity of the myocardium, from which properties 
of the structure and content of collagen and elastin are indirectly derived [35, 36]. 
This method is sensitive to the fiber angle and density, both of which give light 
to the health status of the tissue [35]. Using the known mechanical properties of 
elastin and collagen (i.e., Young’s Modulus), one can distinguish the relative contri-
butions of ECM proteins to the tissue. Finally, cardiac nuclear imaging, including 
single-photon emission computed tomography (SPECT) and positron-emission 
tomography (PET), has been used to quantify the ECM content [25]. Radioactive 
molecular probes are used in these techniques. The common targets include collagen 
type I, II and IV, as well as MMPs [37, 38].
3.2 Optical imaging techniques
Optical imaging techniques are often used to provide the images of collagen 
fibers including their content and fiber orientation in intact, fresh tissues using 
physical properties of photons [39]. Two primary optical imaging techniques are 
the Second-harmonic Generation (SHG) and Small Angle Light Scattering (SALS). 
SHG imaging is a form of nonlinear optical microscopy. It can be applied to fresh 
or fixed tissues at varying depths (optical section), thus revealing the 2D or 3D 
structure of the collagen fibers [40]. This technique is advantageous due to its high 
resolution and specificity for the microstructure of collagen fibers [41]. However, 
it only allows the imaging of samples to a certain distance (depth), and deep tissue 
imaging systems are currently under development to enable larger length of pene-
tration [42]. SALS is another method to measure fiber orientation when a polarized 
light beam is passed through a specimen—biological or nonbiological [43, 44]. The 
distribution of the scattered light is used to identify fiber orientation and align-
ment [43]. The gross/average collagen fiber orientation can be obtained in tissues 
with a thickness of at least 500 microns [45]. The advantage of this technique is the 
capability to measure in thicker tissues than SHG; but the disadvantage is that only 
an average of planar (2D) fiber orientation is derived, and the information along the 
depth direction is unavailable.
3.3 Biochemical and biological measurements
Direct measurements of collagen can be obtained using a long-established bio-
chemical measurement – hydroxyproline assay, which quantifies the hydroxypro-
line content in digested samples. Hydroxyproline is a main molecular component of 
collagen and its amount can indirectly reflect the collagen content or is converted 
to collagen content with assumed collagen to hydroxyproline ratio [46]. Different 
methods have been established to measure hydroxyproline including colorimetric 
methods, high-performance liquid chromatography (HPLC) and liquid chromatog-
raphy-mass spectrometry (LC–MS) [47].
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In addition, tissue staining protocols—histology methods—are convenient to 
examine the ECM protein content and structure without losing the local distribution 
information. The common staining methods for collagen are Masson’s Trichrome 
stains [35, 48] and Picrosirius Red stains [49]. Because mature collagen is birefringent 
and the Picrosirius Red stain can enhance the birefringency of collagen, collagen 
fibers can be visualized better and in more details under polarized light. It also enables 
a quick examination of types I and III collagen in CV tissues due to the different fiber 
thickness [50, 51]. Alternatively, the elastin is often examined by the Verhoeff-Van 
Gieson (VVG) stain [52] and the glycosaminoglycans (GAGs) and proteoglycans are 
examined by the Alcian blue stain [53]. Moreover, immunohistochemistry (IHC) 
employs the use of antibodies to quantify the specific protein of interest [10, 11].
Non-microscopic measurement methods include enzyme-linked immunosor-
bent assay (ELISA) and other standard biological methods. ELISA has been applied 
to detect collagen types I and III, as well as elastin and cross-linking of collagen 
[54, 55]. Finally, like all other proteins, the ECM proteins can be quantified by the 
protein expression using Western blot (immunoblotting) or by the mRNA or DNA 
expression using qPCR (quantitative Polymerase Chain Reaction) [6, 56].
4.  Alterations of biomechanical properties in cardiac disease 
progression
Heart failure (HF) affects approximately 6.2 million adult Americans [57]. The 
main causes of HF are myocardial infarction, pressure-overload (hypertension), 
volume-overload, arrhythmia, valve stenosis or regurgitation, etc. Ventricular 
dysfunction is the most common type of HF including left-sided HF with preserved 
ejection fraction (HFpEF) and reduced ejection fraction (HFrEF), as well as 
right-sided HF secondary to pulmonary hypertension and congenital heart disease 
[58–60]. The malfunction of the myocardium can occur in the LV, RV, or both 
ventricles (biventricular HF).
As shown in the overall scheme (Figure 1), the cardiac ECM remodeling is an inter-
active, dynamic procedure that brings the cellular function, tissue mechanical behav-
ior and organ function into one scenario. The ECM remodeling leads to both biological 
(structural) and mechanical (functional) changes of the tissue, which in turn regulates 
cell behaviors and alters the hemodynamics and cardiac performance. It is accepted 
that the remodeling often starts with an attempt to maintain the homeostasis environ-
ment of the cells and organ. This is referred to as adaptive remodeling (compensation). 
However, when the remodeling cannot achieve a ‘stable’ status of the new homeostasis 
but continues to deteriorate, impairments of the cells and organ will occur. This is 
known as adverse or mal-adaptive remodeling (decompensation). The mechanism of 
transition from compensation to decompensation remains a key knowledge gap. In 
almost all types of HF, cardiac fibrosis plays an important role in the pathogenesis; but 
its effects on mechanical changes of the myocardium and the physiological function 
are less noted. Hence, our discussion here will focus on the maintenance of the biome-
chanical homeostasis in common types of HF involving both LV and RV.
4.1  Biomechanical adaptations of hypertensive (pressure overload) 
myocardium
4.1.1 Fibrotic changes in hypertensive LV and RV
Hypertension is defined as chronically elevated blood pressure in the systemic 
circulation, with a systolic blood pressure greater than 120 mmHg, and/or a 
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diastolic blood pressure greater than 80 mmHg [61]. It is one of the most preva-
lent pathologies in the United States, affecting approximately one in three adults. 
Hypertensive heart disease (HHD) accounts for approximately a quarter of all 
causes of heart failure [61]. In response to the pressure overload, cardiac hypertro-
phy and fibrosis are the most prominent events observed. The increased interstitial 
and perivascular collagen is originated from several cell types including cardiac 
fibroblasts, activated macrophages [62], cells derived from EndMT (or epithelial-
to-mesenchymal transition (EMT)) or myofibroblasts, which are transdifferenti-
ated from EndMT and EMT [21, 63].
In preclinical animal models, HHD can be induced by aortic banding [64, 65], 
genetic alteration (e.g. spontaneous hypertensive rates (SHR)) [66], or other 
methods that overlap with the models of systemic hypertension (e.g. high-salt 
diet or angiotensin II infusion) [63]. From both clinical and animal studies, 
various fibrillar collagen types such as I, III, IV, and V were reported to increase 
in the hypertensive LV [12, 64, 65, 67, 68]. The regulation of collagen turnover 
is dynamic. For instance, collagen types I and III increased within a day after 
hypertension was induced [64, 65]. Collagen types I and III reached a peak content 
(fivefold and 1.7-fold, respectively) at day 3, then decreased at day 7 and plateaued 
four weeks after the aortic banding. In contrast, collagen type IV reached its peak 
one day after the banding, and then began to decline at day 3 and plateaued at 
day 7 [65]. A similar trend of an initial elevation followed by a decline of collagen 
types I, III and IV has been reported by Jalil et al. in a rat aortic banding model 
[64]. The time-dependent change has been suspected to be associated with the 
transition from compensative hypertrophy to decompensation. The overall ECM 
degradation in later stages of HHD is speculated to disrupt the mechanical support 
and electrical conduction for myocardial contraction and promote cardiomyocyte 
apoptosis, which results in impairments of cardiomyocyte contractility and organ 
failure [12, 69].
There is no consensus on whether type I or type III collagen plays a more sig-
nificant role in the LV hypertrophy. Some studies have indicated a predominance 
of type I collagen accumulation [70, 71], but others reported equivalent elevations 
of type I and III [72]. In a patient study that examined the collagen type I and III 
mRNAs expression in dilated cardiomyopathy, it was shown that the collagen type 
III/I ratio was higher in dilated cardiomyopathy patients (idiopathic, hypertensive 
and alcoholic) than the healthy controls [73]. This suggests an important role of 
collagen type III in the hypertensive LV fibrosis. The metabolism of the two collagen 
isoforms may not be independent since it has been shown that type III collagen is 
crucial for collagen I fibrillogenesis during the normal development of cardiovascu-
lar system [74]. Therefore, a further understanding of the role of collagen isoforms 
in fibrosis is needed.
In the RV, similar fibrotic remodeling occurs in response to pulmonary hyper-
tension (PH), which is defined as a mean pulmonary arterial pressure (mPAP) 
exceeding 20 mmHg [75]. Increases in total collagen content or collagen synthesis 
were consistently reported in hypertensive RVs, from clinical to preclinical stud-
ies, from large to small animals, as well as from early to late stage of RV failure 
[50, 76–78]. The types of collagen upregulated in the RV has been investigated 
but inconsistent findings are reported. In a mouse model of PH (Sugen+hypoxia), 
the ratio of collagen type I/III was increased in the diseased RV and it was mainly 
attributed to the increase in type I collagen [78]. But in a recent ovine model of PH, 
type III collagen rather than type I collagen was found to be increased more sig-
nificantly in the RV [51]. While both studies used Picrosirius Red stained histology 
samples to quantify collagen isoforms in the RV, these results need to be confirmed 
by other quantitative methods in future studies.
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Finally, not only is there a change of the collagen content, but the morphol-
ogy, cross-linking, and alignment are altered in the remodeling process. First, in 
the hypertensive LV, collagen type I became thicker and denser, creating a tighter 
mesh of fibers [64]. Second, the increase in collagen content is accompanied 
with an increase in cross-linking as this is part of the maturation of new collagen. 
Cross-linking is an enzymatic driven event and two types of enzymes—the LOX 
(lysyl oxidase) family and TG (tissue transglutaminase)—have been found to be 
upregulated in hypertensive myocardium [79, 80]. It has been shown that the col-
lagen cross-linking, not content, was associated with the LV chamber stiffness and 
filling pressure [80, 81]. Collagen cross-linking was also associated with a higher 
incidence of hospitalization in HHD patients [82]. On the other hand, the cardiac 
remodeling requires degradation of insoluble collagens to enable rearrangement 
of cells and matrix proteins, and reduction in collagen cross-linking was reported 
as well [70]. Therefore, the role of cross-linking has not been fully understood in 
HHD. Third, collagen fibers became more aligned in the hypertensive LV [65]. 
Similarly, enhanced fiber alignment has been reported in the RV. In rat PH RVs, 
the myo-fibers and collagen fibers were more strongly aligned in the longitudinal 
(apex-to-outflow) direction so that the tissue became more anisotropic in mechani-
cal behavior [83].
4.1.2 Mechanical changes in hypertensive LV and RV
Myocardial stiffening is widely evident in HHD patients, particularly revealed 
by the increase in diastolic (passive) stiffness of the LV [65, 67]. The reduced 
mechanical strain is a surrogate of myocardial stiffening and became noticeable 
in hypertensive LVs even when the contractility was preserved [32, 84]. This 
indicates that the stiffening occurs in the early stage of HHD. Increased myocardial 
stiffness is thought to predominantly contribute to the diastolic dysfunction, 
which is evident by increases in isovolumetric relaxation time (IVRT), and end-
diastolic volume or diameter (EDV or EDD) [85, 86]. Moreover, the persistent 
diastolic dysfunction with a dilatation/thinning of the myocardium is associated 
with impaired contractile (systolic) function, which was revealed by changes in 
dP/dtmax, dP/dtmin, end-systolic pressure-volume relations (ESPVR), fractional 
shortening (FS), ejection fraction (EF), stroke volume (SV), or cardiac output 
(CO) [87]. The mechanical changes are of high clinical relevance as the myocardial 
stiffness is significantly greater in the high-risk patients than in healthy controls, 
which may indicate a transition to heart failure with preserved ejection fraction 
(HFpEF) [88]. However, what initiates the transition from adaptive to maladaptive 
remodeling remains unclear.
Like the LV, the RV myocardium stiffens under chronic pressure overload 
[83, 89, 90]. The clinical evidence of RV stiffening in PH patients has been reported 
via the myocardial strain or strain rate measurements [91, 92]. Compared with the 
LV, the RV passive mechanics seem to play a more important role in physiological 
function, which is supported by the findings that the RV elasticity is more closely 
associated with the severity of RV failure and is better related to prognosis than 
the RV systolic function [93–95]. The RV stiffening is also evident from ex vivo 
measurements of RV mechanical properties from a number of preclinical animal 
studies. A significant increase in RV stiffness was noted in the PH group in both 
longitudinal and circumferential directions, with or without cardiomyocytes 
[96, 97]. But some reported a greater change in stiffness in the longitudinal direc-
tion [90], whereas others reported a greater change in the circumferential direction 
[89]. Therefore, the characterization of anisotropic mechanical changes of hyper-
tensive RV needs to be further elucidated.
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The potential clinical significance of RV stiffening has been explored in a few 
studies. Jang et al. found that in PH rats, the RV longitudinal elastic modulus (EM) 
derived at low strains was correlated with RV diastolic function (end-diastolic 
elastance). This is the first report on the linkage of RV tissue mechanics and in vivo 
hemodynamics [90]. Recently, from an ovine model of PH, the RV longitudinal 
stiffness was significantly increased and correlated with the long-axis end-diastolic 
or end-systolic diameter or area. Moreover, in the longitudinal (apex-to-outflow 
tract) direction, there were trends of correlations between the low-strain EM and 
the acceleration time, as well as between the high-strain EM and the decelera-
tion time. These findings indicate the critical role of the RV passive mechanical 
properties in the organ function [98]. Nevertheless, the question remains as to how 
exactly the mechanical changes affect the transition from adaptive to maladaptive 
remodeling.
4.1.3 Different roles of fibrosis in hypertensive LV and RV?
Finally, the role of RV fibrosis in PH development may be different than the 
fibrosis in the hypertensive LV. For instance, RV fibrosis occurs early with the 
pressure overload and no report of collagen degradation has been noted in failing 
RVs. In contrast, collagen degradation has been documented in the late stage of 
LV failure (see Figure 3 below). Second, the RV fibrosis measured by T1 map-
ping was correlated with pulmonary arterial stiffness and RV RAC (relative area 
change), but not correlated with pulmonary pressure, RV mass or ejection frac-
tion in PH patients [99]. This indicates that the RV fibrosis may be an early marker 
of maladaptive RV remodeling before the deterioration in the functional metric 
[99]. Such prognostic role has not been reported in LV fibrosis. Third, different 
outcomes of anti-fibrotic treatment were found between LV and RV. In the LV, 
treatments that induced reduction of fibrosis had led to regression of chamber 
stiffness and function improvement [71, 100–103]. The beneficial outcomes of 
anti-fibrotic treatment are convincing and recently reviewed [104]. But interest-
ingly, interruptions of collagen accumulation in RV had led to various conse-
quences. The restriction of collagen accumulation using a transgenic mouse model 
resulted in limited RV hypertrophy and preserved RF function in PH develop-
ment, indicating a protective role of anti-fibrosis therapy for the RV [78]. Other 
drug studies that demonstrated reduced RV fibrosis and improved RV function 
are briefly summarized by Bogaard et al. [105]. But recently, an anti-fibrotic 
intervention via suppressed Gelectin-3 expression (knock-out mice) or pharma-
ceutical inhibitors was insufficient to improve RV function in PH mice, despite an 
improvement in RV fibrosis [106]. These results raise more questions about the 
role of RV fibrosis in its function. Therefore, whether and how the fibrotic event 
precedes the functional decline in the RV may be organ specific and remains to be 
elucidated. Other different responses of the LV and RV to pressure overload are 
listed in Table 2.
4.2 Biomechanical adaptations in volume overload myocardium
Volume overload is initially learned as physiological responses of myocardium 
because of the reversible myocardial remodeling observed in athletes and women 
in pregnancy. But pathological responses are also found in patients with heart valve 
disease (regurgitation) and congenital heart disease, which alternatively lead to 
heart failure. As a result, different views form regarding whether the remodeling 
from volume overload is adaptive and irreversible [110, 111]. In contrast to pressure 
overload, volume overload is often treated as another type of mechanical ‘insult’ 
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in which the tissue is stretched beyond its normal state during diastole [112–114]. 
Under this type of mechanical load, collagen loss and chamber dilatation occurred 
since the early stage and these changes persisted, leading to an overall decrease in 
cardiac ECM [112–115]. Such remodeling was attributed to an increase in MMP 
activity [113]. But elastin showed biphasic changes in the progression of ECM 
remodeling. Ruzicka et al. reported an initial (within one week of induced volume 
overload) increase in elastin concentration but then a decrease of elastin concentra-
tion below control levels 10 weeks after induced volume overload [114]. The reduc-
tion of ECM turnover in volume overloaded LV was related to a phenotype change 
of fibroblasts into hypofibrotic type [116] and increased MMP expressions from 
macrophages or mast cells [117–119]. An increased collagen III/I ratio was also noted 
in the compensated stage of the remodeling [114]. The elevated ECM degradation 
in volume overloaded LV seems to share common pathways as seen in late stage of 
HHD—to enable ventricle dilatation and thinning and weaken the cell-matrix con-
nections, which impairs contractile function.
The RV did not undergo initial remodeling to the same extent of the LV. It is well 
known that the RV is better in adaptation of the volume overload whereas the LV 
is better in adaptation of the pressure overload [107, 120]. The chamber difference 
also lies in the fact that LV alterations are more widely reported on than those of 
the RV and that the RV has exhibited milder remodeling than the LV [121]. The less 
pronounced remodeling including the ECM alteration of the RV may be explained 
by the different origins and contractile behaviors of cardiomyocytes [120, 122] and, 
thus, different responses to the mechanical stimulations.
Like in pressure overloaded HF, myocardial stiffening also arises in response 
to volume overload and eventually leads to heart failure [123, 124]. For instance, 
Emery et al. reported a 10-fold increase in LV mid-wall stiffness along the fiber 
RV LV
Fibrosis Persistent in all stages Mostly in early stage; 
degradation occurs in late 
stage
Cardiomyocytes ↓ α-MHC and ↑β-MHC (fetal gene 
expression); no atrial natriuretic 
peptide (ANP); inefficient energy 
metabolism
↑β-MHC only; ↑ ANP; 
Improved energy metabolism
Collagen isoforms Type I and III Type I, III, V, IV, VIII, and 
more
Collagen fiber More aligned fibers into apex-to-outflow 
tract direction
Thicker, denser collagen 
type I, more cross-linking & 
aligned fibers
Dilatation Occurs acutely in early stage Occurs in late stage





Yes (macrophages, TNF-α, IL-1β) Yes (T lymphocytes, TNF-α, 
IL-1β)
Response to anti-fibrosis 
treatment




Different responses of the LV and RV to pressure overload. MHC: myosin heavy chain; ANP: atrial natriuretic 
peptide. Adapted from [107–109].
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direction and the cross-fiber direction six weeks after volume overload induc-
tion [125]. The underlying cause of the myocardial stiffening is investigated by 
collagen measurement. Interestingly, despite the decrease in the relative collagen 
content, there was an upregulation of collagen cross-linking [115]. A similar finding 
was identified using hydroxylysylpyridinoline (HP) assay in minipig LVs [126]. 
Therefore, despite a decrease in total collagen content, the tissue stiffening occurs 
due to elevated cross-linking in these ventricles [115, 125, 126].
Myocardial compliance, however, showed different trends of changes than the 
intrinsic (material) mechanical property of the myocardium. This is because the 
chamber compliance is a measurement of overall stiffness that incorporates changes 
in the intrinsic mechanical property, the geometry of the wall (dilatation and thin-
ning) and the contractility of the heart (ventricular pressure). In the acute stage, 
the LV wall dilated and the compliance increased 2 days after induction of volume 
overload [112]. Similar findings are reported in the compensated stage. A signifi-
cant decrease in the end-diastolic pressure-volume relationship (EDPVR) and a 
right shift of the pressure-volume loop were seen in the group with 8-week volume 
overload [127]. This indicated increased compliance and chamber dilatation. But 
at 15–21 weeks of volume overload, there was no significant change in the EDPVR 
compared to that at week 8 [127]. Thus, the maintained compliance may be a com-
bined results of increased intrinsic stiffness and decreased myocardial thickness.
4.3 Different myocardial remodeling induced by pressure and volume overload
Both pressure overload and volume overload are categorized as the hemody-
namic (mechanical) ‘insult’ of the myocardium. The pressure overload is consid-
ered as an afterload increase whereas the volume overload is considered as a preload 
increase. Therefore, the main mechanical stimulus difference lies in the ‘phase’ – 
systolic phase for pressure overload and diastolic phase for volume overload, during 
which the cells sense increased wall stress or stretch. The comparison of physi-
ological changes and cellular responses are reviewed previously [110, 111, 128], 
and temporal myocardial responses to pressure overload and volume overload are 
summarized in Figures 2 and 3.
Figure 2. 
Temporal changes in myocardial fibrosis, wall stiffening and physiological function in pressure overload 
induced heart failure progression.
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The initial (early) remodeling of these two types of overload is different, leading 
to concentric remodeling (reduced volume and increased wall thickness (h) to 
radius (r) ratio) in pressure overload and eccentric remodeling (increased volume 
and reduced h/r ratio) in volume overload. Sometimes these changes are considered 
as ‘adaptive’ since the wall stress was normalized by the remodeling (according 
to Law of Laplace). However, at the cellular level, the ‘growth’ of cardiomyocytes 
is in width (pressure overload) and in length (volume overload), respectively. 
Interestingly, it remains unclear why and how the cardiomyocytes respond to 
the higher stress at passive and active states differently. Furthermore, as pointed 
by Pitoulis et al., the late remodeling of these two types of overload ‘converges’, 
indicating some common pathways shared in the decompensation stage [128]. The 
convergence could be caused by a co-existence of these mechanical overloads in 
the same patient or by the key shared pathways that lead to irreversible remodeling 
at the late stage of heart failure. These are important questions that remain to be 
investigated to further improve the clinical management of non-ischemic heart 
failure patients.
4.4 Biomechanical adaptations in myocardial infarction (ischemia)
Myocardial infarction (MI) is caused by a reduction of blood perfusion in 
coronary arteries and necrosis—cardiomyocyte cell death [130]. This is the most 
studied type of heart failure, and there are numerous reviews on ECM changes in 
MI [1, 2, 21]. Acute and chronic MI lead to significant inflammatory and fibrotic 
responses by recruitment and activation of neutrophils, macrophages and (myo)
fibroblasts. Interstitial and perivascular fibrosis from both replacement and reac-
tive types of collagen accumulation greatly reduces the cardiomyocyte population 
and muscle contractility. The failure to resolve the fibrotic region (scar) results in 
a continuous stiffening and dilatation of myocardium and irreversible HF [105]. 
Compared to the LV, the RV is less susceptible to ischemic injury and it can recover 
after prolonger coronary occlusion [131, 132]. Therefore, our discussion below is 
mainly focused on the LV.
The initial response of MI is a cascade of events including the release of MMPs 
and proteases, which is thought to trigger the post-MI inflammatory response and 
Figure 3. 
Temporal changes in myocardial fibrosis, wall stiffening and physiological function in volume overload induced 
heart failure progression.
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to degrade the ECM following proliferative phase [12]. Then, collagen deposition 
is seen most prevalently in the infarcted region, creating a fibrotic scar [133]. The 
injured region can be clearly identified, with a high-density mesh of small diam-
eter, aligned collagen fibers [134]. Both collagen types I and III were increased in 
infarcted LVs [134, 135]. Cleautiens et al. found that type I procollagen expression 
was increased and peaked by 10-fold four days post-MI, and the elevation remained 
90 days after infarction. A similar trend was seen in type III procollagen, however 
its levels reached a peak later at day 21 post-MI [135]. Alternatively, experimental 
work also shows that the procollagen type III induction occurs earlier than that 
of procollagen I [136]. Other fibrillar collagen, such as types V and VI, increased 
in infarcted areas; for instance, the content of type VI peaked two weeks post-MI 
[137]. Elastin content was found to increase initially, but it rapidly decreased to 
values lower than the healthy tissue [134].
Moreover, regional changes occur in the non-infarcted zones. In the rat LV, 
collagen concentration increased by 50% in the infarcted region, whereas only 
a 27% increase was reported in the remote region [138]. Furthermore, collagen 
cross-linking only occurred in the infarcted zone and not in the remote region 
[138]. Similarly, there was a gradient of changes in the mechanical properties 
in different regions. The infarcted region showed mechanical alterations to the 
highest degree; the border zone showed moderate changes, and the remote region 
showed little to no change [139]. ECM remodeling also arises in the septum and RV 
with infarcted LV [135]. A 4–5 folds increase in expression of procollagen types I 
and III mRNA was observed in the septum within three weeks post-MI, followed 
by a decline to control levels. A less but significant elevation of collagen types I 
and III also occurred in the RV, with levels of type III remaining elevated 90 days 
post-MI [135].
The injured area post-MI is predominantly a fibrotic scar with time-dependent 
changes in mechanical properties. Torres et al. found that the myocardial stiffness 
increased initially in the MI region, then in the border zone and the remote region. 
At 28 days post-MI, the myocardial longitudinal stiffness in all three regions 
decreased, and the reduction was most notable in the MI region with a 40% 
decrease [139]. Decreases in stiffness in the infarcted zone in late MI have been 
documented in other studies: the tissue becomes more compliant and more iso-
tropic compared to the healthy tissue [140]. The initial increase in stiffness can be 
attributed to deposition of collagen and increased collagen isotropy [141]. At later 
stages, tissue became softer (e.g., 6–8 weeks post-MI) due to collagen degradation 
[131, 132, 140, 141]. These biomechanical changes are speculated to contribute 
to the further thinning and dilation of the myocardium leading to irreversible 
HF. Thus, the end-stage of HF due to MI, pressure overload and volume overload 
seem to share some common pathways associated with similar biomechanical 
alterations.
4.5 Biomechanics of heart valves
4.5.1 Biomechanical alterations in heart valve disease
Heart valve disease can occur as a result of various causes such as aging, birth-
defects, or infections. Depending on the mechanical abnormalities, the heart valve 
disease can be categorized into two types—stenosis (with reduced opening of 
valves) and regurgitation (with incomplete closure of valves). These mechanical 
changes will increase the mechanical load of the ventricle and reduce cardiac out-
put. Often the disease progression involves a mix of pressure and volume overloads 
and biventricular dysfunction. Aortic valve disease (AVD) is the most studied 
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heart valve disease and involves high levels of ECM degradation and calcification. 
For instance, collagen I and III decreases resulted in decreased valve stiffness 
[142]. But the aggregation of calcium hydroxyapatite (calcification) that replaces 
degraded collagen can lead to an ultimate stiffening of the valve leaflets. We recom-
mend the reader to these thorough reviews of the biomechanical changes of heart 
valves in heart valve disease [143–145].
4.5.2 Role of ECM in the mechanics of heart valves
In healthy valve leaflets, collagen makes up ~90% of the ECM and thus is the 
main load-bearing component. Elastin, proteoglycans, and GAGs also contribute 
to the mechanical properties of the heart valves. This dense connective tissue is 
highly organized and present special viscoelastic mechanical behavior (minimal 
creep but significant stress relaxation) [146]. Therefore, any changes in the collagen 
fiber orientation or ECM proteins will induce mechanical dysfunction and thus 
abnormal opening/closing of the valves. The necessity of investigation of valve 
ECM is recently reviewed [143]. Furthermore, for the atrioventricular valve (i.e., 
mitral valve or tricuspid valve), the additional connection of the leaflets (LL) to the 
chordae tendineae (CT) and then further to papillary muscles (PM) has extended 
the research into transition regions of LL-CT and CT-PM. Because CT rupture is the 
primary cause of valve regurgitation, the mechanical properties of these regions 
are critical to delineate the pathology. Advanced methodologies on collagen fiber 
quantification (e.g., X-ray diffraction) and computational models were recently 
adopted to investigate the macro- and micro-mechanical properties of these transi-
tion regions [147, 148], although the research has been mostly focused on healthy 
tissues. A nice review of the microstructural mechanical characterization on CT of 
valves is referred here [149].
Collagen fibers in the CT contribute greatly to the overall function of the 
valve [147]. From the mitral valve (MV), collagen fibers found in the CT form a 
‘core’ that are oriented longitudinally, with another group of collagen fibers that 
wrap around the core, offset from the primary axis [150]. Conversely, it has been 
observed that the CT extending from the tricuspid valve (TV) consists of smaller 
diameter of fibers but in higher densities than the MV [151]. This difference 
in collagen formation is a result of the mechanical needs of each CT, as the TV 
experiences lower loading than the MV. In diseased valves such as myxomatous 
degeneration of the mitral valve (MDMV), collagen deposition and myofibroblasts 
activation are observed. Although accumulation of collagen fibers is often associ-
ated with increased stiffness, the CT in MDMV actually becomes more compliant. 
Barber et al. found that the elastic modulus (EM) of healthy CT (132 ± 15 MPa), as 
well as the failure strength (25.7 ± 1.8 MPa), were significantly higher than those of 
diseased CT in MDMV (40.4 ± 10.2 MPa and 6.0 ± 0.6 MPa, respectively) [152]. A 
similar finding was also observed in other valve diseases: myxomatous degenera-
tion of the tricuspid valve by Lim et al. [153], as well as by Casado et al. in the calci-
fied mitral valve CT [154]. In such cases, the collagen fibers in the center core of 
the CT became disorganized and were no longer formed in tight bundles as they do 
in healthy CT [153]. Therefore, the altered alignment and dis-organization of the 
collagen fibers reduce the overall stiffness as well as the tensile strength of the CT.
5. Mechanobiology of cardiac cells
As we discussed above, ECM remodeling is a critical part of tissue’s response 
to altered mechanical loads or other pathological stimulations (e.g., ischemia) 
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[112–114, 155–160]. This leads to dynamic alterations of the myocardial mechani-
cal properties including the anisotropic, nonlinear elastic behavior as well as the 
viscoelastic behavior. The clinical relevance of ventricular mechanical behavior has 
been recently reviewed by our group [76]. In this chapter, we will focus on another 
impact – the cellular response to substrate biomechanical properties. Because of the 
prominent role of fibrillar collagen in myocardial mechanical behavior (especially 
in diseased tissues), we will mainly discuss the cellular response caused by fibrillar 
collagen deposition. The influence of other ECM proteins on cardiac cells during HF 
progression is reviewed in these references [12, 161].
The cardiac cell’s response to mechanical factors has been mostly investigated 
by exposing cells to steady or cyclic stretches to mimic myocardial contraction. 
Compared to the unstretched condition, there was significant increase in procol-
lagen type I activity in cultured fibroblasts under cyclic stretching [156, 157]. 
Alternatively, Carver et al. evaluated the change in collagen III/I ratio in isolated 
cardiac fibroblasts. After 12 hours of cyclic loading, there was a 70% increase in 
the ratio of type III to type I collagen compared to unstretched cells [158]. Not only 
the collagen synthesis but also the degradation signaling pathway are upregulated 
by the mechanical loads. Multiple studies have found an upregulation of MMPs, 
particularly MMP-2 and MMP-9, in response to mechanical stretches compared to 
unstretched conditions [113, 155, 159]. Since the expression of collagen or procol-
lagen was greater than that of MMP’s, a net increase in collagen was observed 
[155]. This mechanical regulation can be attributed to higher levels of transform-
ing growth factor beta 1 (TGF-β1), which stimulates fibroblast’s growth and 
transdifferentiation and ECM protein synthesis [155, 160]. However, while these 
findings strongly advocate the mechanical regulation of cardiac fibroblasts and 
fibrogenesis, the unstretched condition is non-physiological and thus it is difficult 
to directly translate the findings into pathogenesis of fibrosis and heart failure.
More in-depth investigation of the substrate’s mechanical regulation is per-
formed by varying the magnitudes of mechanical strains or comparing the effects 
of tensile stretch and compression. For example, after 24 hours of culture of 
cardiac fibroblasts, Lee et al. found that the expression of collagen type I mRNA 
significantly increased at uniaxial strain of 10% but showed no change at 20% 
strain. In contrast, type III collagen mRNA expression significantly increased 
at 10% strain but decreased at 20% strain. The response of collagen type III was 
more prominent than collagen type I [160]. In compression though, no significant 
change was noted in type I or III collagen mRNA. The different response between 
stretch and compression is intriguing as it implies that it is the mechanical signal in 
diastole (stretching of wall), not in systole (compression of wall), that stimulates 
the fibrotic response in fibroblasts. But a discrepant result is also reported. Kong 
et al. observed at compressive cyclic loading (5–20% strain) an upregulation in 
collagen type I and TGF-β1 expression [155], whereas Lee et al. reported significant 
increases only in TGF-β1 expression and no notable changes in collagen type I at 6% 
compressive strain compared to unstretched cells [160].
Besides the mechanical forces, it is also critical to investigate if and how the 
mechanical stiffness of the substrate affects cellular function. To date, a few in vitro 
studies have reported the regulation of matrix stiffness using synthetic hydrogels 
tuned to match the stiffness of healthy and diseased myocardial tissues. When 
cultured on different stiffness of poly (ethylene glycol) (PEG) hydrogels, cardiac 
fibroblasts were activated into myofibroblasts by increased stiffness (6 vs. 60 kPa) 
and addition of TGF-β1 stimulation. Furthermore, only the condition medium 
from fibroblasts cultured on stiff matrix treated with TGF-β1 caused neonatal rat 
ventricular myocytes enlargement, indicating a synergistic effect of matrix stiffness 
and TGF-β1 on the activation of myofibroblasts and myocyte hypertrophy [162]. In 
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addition, the fibroblasts responded to the dynamic stiffening of the PEG hydrogel 
(from 10 to 50 kPa) by increasing cell spread area and reducing nuclei round-
ness within 2–5 days of culture, mimicking the in vivo observation of phenotype 
changes of fibroblasts [163]. Increased fibroblast cells spreading and collagen type I 
expression, and decreased collagen III expression were reported in stiffer matrix 
Biomechanical Cue Cell Type Main Finding Ref
Polyacrylamide gel with 
varying stiffnesses: 8 kPa, 
15 kPa, 50 kPa, 100 kPa 




Contracting force of the CM 
tends to increase with matrix 
stiffness. Contractile function, 
though, is normalized when 
the matrix stiffness was 
returned to healthy levels
[165]
PDMS surfaces with varying 
stiffnesses: 1 kPa, 6 kPa, 
20 kPa, 130 kPa (embryonic 




On soft surfaces, CM exhibits 
greater contraction than those 
on stiff surfaces. Sarcomeres 
show faster shortening speeds 
on soft surfaces. TGF-β1 is 
more prevalent on stiffer 
surfaces
[166]
PEG hydrogels with varying 
stiffnesses: 10 kPa (healthy 
neonatal heart), 35 kPa 
(diseased neonatal heart)
Neonatal Rat Ventricular 
Cardiomyocytes (CM)
Regardless of matrix stiffness, 
myocytes spontaneously 
contract and form healthy, 
organized sarcomeres. 
However, fractional 
shortening increased only on 
soft gels
[167]
Collagen type I matrix 
morphology (fibrous vs. 




Non-fibrous collagen leads 
to cells with higher filopodia 
(actin-rich protrusions) and 
higher CD206 expression, 
whereas stiffness has no 




polyacrylamide gels with 
varying stiffness: soft 
(1–5 kPa) to represent 




Human Macrophages Stiffer substrates leads to 
larger cell spread area, faster 
migration speed, less dense 
but more organized F-actin, 
and increased proliferation 
rate
[169]
Polyacrylamide Gel with 
varying stiffness: 1.2 kPa to 
represent normal lungs and 
150 kPa to represent fibrotic 
lungs
Mouse macrophages Cell elasticity increases with 
increased matrix stiffness; 
and cell elasticity is a major 
determinant of innate 
macrophage function
[170]
PEG-RGD hydrogel with 
tangent (compressive) 
modulus from 130 kPa to 
840 kPa
Mouse macrophages Stiffer hydrogel leads to 
larger cell spread area and 
more extended branches of 
actin, activation of pro-
inflammatory cytokines, and 




Summary of in vitro studies of matrix stiffness dependent changes in cell behavior and function.
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(3 vs. 8 kPa), which is postulated to imitate the late stage MI heart with matured 
scar formation [164]. In the same study, it was also found that the cross-linking of 
collagen was ‘triggered’ by non-equibiaxial static stretch mimicking in vivo strains 
in the border region rather than the matrix stiffening. While this experiment 
design de-couples the mechanical stretch and stiffness, it must be noted that in 
physiological conditions, these two factors are not independent – a stiffer material 
will result in reduced stretch/strain under the same pressure. We have listed a few 
in vitro studies that investigated the responses of cardiomyocytes or macrophages 
to substrate stiffness in Table 3. These pilot studies highly support a role of ECM 
mechanical properties in cellular regulation relevant to cardiac ECM remodeling. 
Overall, the area of cardiac mechanobiology is still very young, as we reviewed 
recently [76]. The discrepant elastic moduli reported from literature and different 
matrix stiffness ranges selected by various groups have increased the difficulty to 
delineate the cellular responses in the progression of cardiac diseases. Therefore, 
future studies should aim to further elaborate the role of matrix mechanics (stretch/
strain, stiffness, etc.) in heart failure development.
6. Conclusions
The cardiac ECM is critical in maintaining cardiac tissue structure and func-
tion. Many studies have been conducted to measure ECM proteins in healthy and 
diseased myocardium to better understand their roles in cardiac remodeling – 
including the biomechanical changes. Our review shows that the ECM remodeling 
(particularly collagen accumulation) in HF is both spatially and temporally depen-
dent. We have compared the myocardial collagen deposition, wall stiffening and 
systolic and diastolic dysfunction between early and late stages of various types of 
HF. While the initial remodeling events being quite different among these diseases, 
common biomechanical changes are shared in the end-stage of HF – ECM degrada-
tion with persisted cross-linking, which are associated with thinning and dilatation 
of the myocardial wall. However, the relation of cardiac fibrosis to the transition 
from compensation to decompensation remains to be elucidated. Furthermore, 
we have high-lighted different responses of the LV and RV to ‘identical stimulus’ 
(pressure overload, volume overload and ischemia). The interventricular difference 
should be another important future direction of research, which may help to bring 
new insights into the pathogenesis and treatment for ventricular failure.
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